Beijing Hotgen Biotech Soars 13.04%, Hits Intraday High of CNY 84.89

Beijing Hotgen Biotech Co., Ltd. has experienced a significant surge in its stock price, gaining 13.04% on June 29, 2026. The stock reached an intraday high of CNY 84.89, marking a notable performance against the backdrop of the China Shanghai Composite, which only rose by 1.16% on the same day. In terms of recent performance, Beijing Hotgen has shown resilience over the past week, with a 5.58% increase, contrasting with a decline of 2.14% in the broader market. However, the company's longer-term performance reveals challenges, with a year-to-date decline of 47.6% and a one-year drop of 37.12%. Despite these fluctuations, the company operates within the mid-cap segment of the Pharmaceuticals & Biotechnology industry, with a market capitalization of CNY 7,297 million. Financial metrics indicate a complex picture, including a negative return on equity of -11.89% and a price-to-book ratio of 3.00. The stock's recent activity highlights its volatility and the ongoing challenges it faces in the market.